We at CPS recognize the great potential for cannabis-based medications to achieve breakthrough solutions for various disease states. We support the State of Connecticut’s designations of thirty disease states as warranting treatment within Connecticut’s medical marijuana program. In response, as a licensed producer of marijuana in Connecticut, we have undertaken the clinical research necessary to establish, at the level of confidence appropriate in American medicine, precisely how cannabis-based medication works on each disease state and precisely what dose levels are warranted.
Since CPS began shipping product to patients at the end of 2014, CPS began gathering information on the impact of its products.
Cachexia Study – Yale School of Medicine
During 2015, CPS began research efforts at the Yale School of Medicine. This first study concerns cachexia, the wasting syndrome that often accompanies serious illness. If we can understand the mechanism through which the body begins to reject nutrition, perhaps we can reverse the condition and improve the nutrition of those fighting serious disease.
PTSD Study – Yale School of Medicine
Our second study at Yale School of Medicine involves establishing the blood levels of cannabinoids necessary to control PTSD and other nerve system disorders. The first phase of the study involves taking blood samples over several hours of patients under treatment to better understand safety and dosing specifics. This information will be used to develop dosing formulations for future PTSD study phases.
Agricultural biotechnology collaboration – University of Connecticut
CPS has undertaken research directed at the cultivation process of cannabis as a medication. Working with UConn, we are examining breeding and cultivation practices in order to create the best products on the market today.
Collaboration with private industry
Within private industry, we have worked at the genetic level on improving cannabis production practices.
One collaboration resulted in a commercially available test kit for sexing cannabis cotyledons. Growers using seeds no longer need to wait for maturity to assess plant gender. They can now use a PCR method for fast, accurate results.
We have also partnered in the validation of a commercially available test kit for identifying cannabis pathogens using genetic sequencing methods.